Tralokinumab
Tralokinumab
Tralokinumab (pronounced trah-loh-KIN-yoo-mab) is a monoclonal antibody designed for the treatment of moderate-to-severe atopic dermatitis. It is developed by Leo Pharma and was approved by the FDA in 2021.
Etymology
The name "Tralokinumab" is derived from its function. "Tralo" is short for "transforming growth factor", "kinu" is derived from "cytokine", and "mab" stands for "monoclonal antibody".
Mechanism of Action
Tralokinumab works by blocking the action of the cytokine IL-13, which is known to play a key role in the inflammatory response that contributes to the development of atopic dermatitis.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Atopic Dermatitis: A type of inflammation of the skin (dermatitis).
- IL-13: A cytokine secreted by many cell types, but especially T helper type 2 (Th2) cells, that is a mediator of allergic inflammation and disease.
- Cytokine: A type of protein that is secreted by immune cells and acts to regulate and mediate immunity, inflammation, and hematopoiesis.
See Also
External links
- Medical encyclopedia article on Tralokinumab
- Wikipedia's article - Tralokinumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski